Financial Ratios Caplin Point Laboratories Limited NSE India S.E.
Stocks
CAPLIPOINT
INE475E01026
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,671.50 INR | +0.88% |
|
+5.66% | +45.34% |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 14.73 | 14.1 | 12.68 | 12.81 | 12.42 | |||||
Return on Total Capital | 16.54 | 15.99 | 14.54 | 14.69 | 14 | |||||
Return On Equity % | 23.28 | 22.74 | 22.06 | 21.69 | 20.68 | |||||
Return on Common Equity | 28.54 | 26.83 | 25.67 | 24.29 | 22.66 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 54.76 | 54.96 | 53.74 | 55.42 | 58.67 | |||||
SG&A Margin | 9.66 | 9.08 | 9.34 | 8.47 | 9.17 | |||||
EBITDA Margin % | 30.92 | 31 | 29.96 | 32.47 | 33.44 | |||||
EBITA Margin % | 27.61 | 27.51 | 27.13 | 29.53 | 30.27 | |||||
EBIT Margin % | 27.61 | 27.51 | 27.13 | 29.53 | 30.27 | |||||
Income From Continuing Operations Margin % | 23.67 | 24.27 | 25.67 | 27.2 | 27.9 | |||||
Net Income Margin % | 22.8 | 23.59 | 25.63 | 26.95 | 27.65 | |||||
Net Avail. For Common Margin % | 22.8 | 23.59 | 25.63 | 26.95 | 27.65 | |||||
Normalized Net Income Margin | 17.62 | 18.29 | 19.18 | 20.57 | 21.68 | |||||
Levered Free Cash Flow Margin | 13.69 | 3.57 | 2.92 | 1.87 | 6.9 | |||||
Unlevered Free Cash Flow Margin | 13.78 | 3.61 | 2.95 | 1.9 | 6.92 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.85 | 0.82 | 0.75 | 0.69 | 0.66 | |||||
Fixed Assets Turnover | 3.54 | 4.2 | 3.75 | 3.24 | 3.15 | |||||
Receivables Turnover (Average Receivables) | 4.18 | 4.24 | 4.08 | 3.59 | 3.27 | |||||
Inventory Turnover (Average Inventory) | 2.3 | 2.82 | 2.63 | 2.32 | 2.29 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.25 | 6.25 | 5.8 | 5.71 | 6.97 | |||||
Quick Ratio | 5.37 | 4.08 | 4 | 4.01 | 5.19 | |||||
Operating Cash Flow to Current Liabilities | 1.86 | 1.62 | 1.01 | 0.96 | 1.41 | |||||
Days Sales Outstanding (Average Receivables) | 87.41 | 86.18 | 89.51 | 101.97 | 111.69 | |||||
Days Outstanding Inventory (Average Inventory) | 158.43 | 129.55 | 138.52 | 157.62 | 159.16 | |||||
Average Days Payable Outstanding | 66.1 | 74 | 78.98 | 79.72 | 105.35 | |||||
Cash Conversion Cycle (Average Days) | 179.74 | 141.73 | 149.05 | 179.87 | 165.5 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.53 | 0.14 | 0.29 | 0.08 | 0.17 | |||||
Total Debt / Total Capital | 1.51 | 0.14 | 0.29 | 0.08 | 0.17 | |||||
LT Debt/Equity | 0.04 | 0.08 | 0.05 | 0.04 | 0.1 | |||||
Long-Term Debt / Total Capital | 0.04 | 0.08 | 0.05 | 0.04 | 0.1 | |||||
Total Liabilities / Total Assets | 11.75 | 13.04 | 12.97 | 13.02 | 10.02 | |||||
EBIT / Interest Expense | 184.53 | 499.46 | 510.72 | 642.22 | 962.33 | |||||
EBITDA / Interest Expense | 207.06 | 564.01 | 565.38 | 707.58 | 1.07K | |||||
(EBITDA - Capex) / Interest Expense | 162.72 | 433.76 | 317.35 | 520.63 | 751.7 | |||||
Total Debt / EBITDA | 0.06 | 0.01 | 0.01 | 0 | 0.01 | |||||
Net Debt / EBITDA | -1.36 | -1.29 | -1.46 | -1.33 | -1.35 | |||||
Total Debt / (EBITDA - Capex) | 0.07 | 0.01 | 0.02 | 0 | 0.01 | |||||
Net Debt / (EBITDA - Capex) | -1.74 | -1.68 | -2.6 | -1.8 | -1.92 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 22.96 | 19.64 | 15.53 | 15.51 | 14.35 | |||||
Gross Profit, 1 Yr. Growth % | 31.19 | 20.09 | 12.97 | 19.12 | 21.06 | |||||
EBITDA, 1 Yr. Growth % | 26.5 | 19.96 | 11.7 | 25.16 | 17.8 | |||||
EBITA, 1 Yr. Growth % | 27.95 | 19.19 | 13.94 | 25.75 | 17.19 | |||||
EBIT, 1 Yr. Growth % | 27.95 | 19.19 | 13.94 | 25.75 | 17.19 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 16.9 | 22.68 | 22.22 | 22.4 | 17.27 | |||||
Net Income, 1 Yr. Growth % | 12.68 | 23.76 | 25.49 | 21.48 | 17.33 | |||||
Normalized Net Income, 1 Yr. Growth % | 11.2 | 24.16 | 21.14 | 23.88 | 20.56 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.45 | 23.81 | 25.27 | 21.8 | 17.28 | |||||
Accounts Receivable, 1 Yr. Growth % | 22.01 | 14.57 | 24.3 | 36.79 | 17.44 | |||||
Inventory, 1 Yr. Growth % | -24.86 | 26.98 | 26.8 | 25.96 | -7.42 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.48 | -5.92 | 66.76 | 13.78 | 21.01 | |||||
Total Assets, 1 Yr. Growth % | 21.13 | 27.33 | 26.21 | 23.12 | 18.89 | |||||
Tangible Book Value, 1 Yr. Growth % | 32.51 | 30.81 | 31.53 | 26.25 | 25.48 | |||||
Common Equity, 1 Yr. Growth % | 32.59 | 30.95 | 31.29 | 26.16 | 25.48 | |||||
Cash From Operations, 1 Yr. Growth % | 494.88 | 25.37 | -19.41 | 17.33 | 35.8 | |||||
Capital Expenditures, 1 Yr. Growth % | -8.15 | 24.34 | 112.18 | -24.63 | 31.34 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -199.63 | -68.16 | -5.55 | -29.83 | 328.17 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -200.45 | -68.07 | -5.38 | -29.51 | 322.79 | |||||
Dividend Per Share, 1 Yr. Growth % | 20 | 33.33 | 12.5 | 11.11 | 20 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 27.94 | 21.29 | 17.56 | 15.52 | 14.93 | |||||
Gross Profit, 2 Yr. CAGR % | 28.66 | 25.51 | 16.47 | 16 | 20.08 | |||||
EBITDA, 2 Yr. CAGR % | 19.18 | 23.18 | 15.73 | 18.24 | 21.43 | |||||
EBITA, 2 Yr. CAGR % | 18.69 | 23.49 | 16.54 | 19.7 | 21.39 | |||||
EBIT, 2 Yr. CAGR % | 18.69 | 23.49 | 16.54 | 19.7 | 21.39 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 19.34 | 19.75 | 22.45 | 22.31 | 19.8 | |||||
Net Income, 2 Yr. CAGR % | 17.14 | 18.09 | 24.62 | 23.47 | 19.39 | |||||
Normalized Net Income, 2 Yr. CAGR % | 14.9 | 17.5 | 22.64 | 22.5 | 22.21 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 16.84 | 17.99 | 24.54 | 23.52 | 19.52 | |||||
Accounts Receivable, 2 Yr. CAGR % | 32.22 | 18.23 | 19.46 | 30.39 | 26.75 | |||||
Inventory, 2 Yr. CAGR % | 118.64 | -2.32 | 26.89 | 26.38 | 7.99 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 15.35 | 1.02 | 25.25 | 37.74 | 17.34 | |||||
Total Assets, 2 Yr. CAGR % | 35.52 | 24.19 | 26.77 | 24.66 | 20.99 | |||||
Tangible Book Value, 2 Yr. CAGR % | 35.16 | 31.66 | 31.17 | 28.87 | 25.87 | |||||
Common Equity, 2 Yr. CAGR % | 35.4 | 31.77 | 31.12 | 28.7 | 25.82 | |||||
Cash From Operations, 2 Yr. CAGR % | 78.49 | 174.54 | 0.51 | -2.76 | 26.23 | |||||
Capital Expenditures, 2 Yr. CAGR % | 3.99 | 9 | 62.43 | 26.46 | -0.51 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 151.65 | -44.23 | -45.16 | -16.46 | 72.16 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 152.71 | -43.93 | -45.04 | -16.22 | 71.48 | |||||
Dividend Per Share, 2 Yr. CAGR % | 16.77 | 26.49 | 22.47 | 11.8 | 15.47 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 25.31 | 25.11 | 19.34 | 16.88 | 15.13 | |||||
Gross Profit, 3 Yr. CAGR % | 25.27 | 25.73 | 21.18 | 17.35 | 17.66 | |||||
EBITDA, 3 Yr. CAGR % | 19.02 | 19.44 | 19.21 | 18.79 | 18.09 | |||||
EBITA, 3 Yr. CAGR % | 18.52 | 18.86 | 20.22 | 19.53 | 18.86 | |||||
EBIT, 3 Yr. CAGR % | 18.6 | 18.86 | 20.22 | 19.53 | 18.86 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.24 | 20.44 | 20.57 | 22.43 | 20.6 | |||||
Net Income, 3 Yr. CAGR % | 18.72 | 19.31 | 20.51 | 23.57 | 21.39 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.67 | 17.91 | 18.7 | 23.05 | 21.85 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 18.49 | 19.12 | 20.37 | 23.62 | 21.4 | |||||
Accounts Receivable, 3 Yr. CAGR % | 30.44 | 26.05 | 20.3 | 24.98 | 25.93 | |||||
Inventory, 3 Yr. CAGR % | 84.6 | 82.42 | 6.56 | 26.58 | 13.92 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 19.52 | 7.77 | 19.39 | 21.3 | 31.92 | |||||
Total Assets, 3 Yr. CAGR % | 39.67 | 32.73 | 24.86 | 25.54 | 22.7 | |||||
Tangible Book Value, 3 Yr. CAGR % | 38.47 | 33.69 | 31.62 | 29.51 | 27.73 | |||||
Common Equity, 3 Yr. CAGR % | 38.56 | 33.9 | 31.61 | 29.44 | 27.61 | |||||
Cash From Operations, 3 Yr. CAGR % | 58.7 | 59.22 | 82.46 | 5.83 | 8.69 | |||||
Capital Expenditures, 3 Yr. CAGR % | 13.25 | 11.84 | 36.1 | 25.75 | 28.07 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 102.67 | 25.5 | -33.52 | -39.43 | 43.38 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 103.28 | 25.98 | -33.24 | -39.26 | 43.06 | |||||
Dividend Per Share, 3 Yr. CAGR % | 14.47 | 22.05 | 21.64 | 18.56 | 14.47 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 28.03 | 25.91 | 22.15 | 21.18 | 17.56 | |||||
Gross Profit, 5 Yr. CAGR % | 31.32 | 27.11 | 21.67 | 21.75 | 20.74 | |||||
EBITDA, 5 Yr. CAGR % | 30.86 | 25.89 | 17.69 | 18.95 | 20.09 | |||||
EBITA, 5 Yr. CAGR % | 31.09 | 25.67 | 17.72 | 19.19 | 20.69 | |||||
EBIT, 5 Yr. CAGR % | 31.09 | 25.67 | 17.77 | 19.19 | 20.69 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 33.9 | 26.43 | 21.12 | 21.18 | 20.26 | |||||
Net Income, 5 Yr. CAGR % | 32.91 | 25.68 | 21.05 | 20.95 | 20.06 | |||||
Normalized Net Income, 5 Yr. CAGR % | 31.44 | 25.06 | 19.02 | 19.73 | 20.09 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 32.59 | 25.42 | 20.87 | 20.86 | 20.03 | |||||
Accounts Receivable, 5 Yr. CAGR % | 103.8 | 57.5 | 25.93 | 27.82 | 22.84 | |||||
Inventory, 5 Yr. CAGR % | 56.92 | 59.1 | 58.9 | 57.51 | 7.13 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 16.74 | 13.78 | 21.78 | 18.89 | 18.56 | |||||
Total Assets, 5 Yr. CAGR % | 38.54 | 37.11 | 34.36 | 29.44 | 23.3 | |||||
Tangible Book Value, 5 Yr. CAGR % | 49.75 | 41.26 | 35.5 | 31.74 | 29.29 | |||||
Common Equity, 5 Yr. CAGR % | 49.84 | 41.33 | 35.53 | 31.79 | 29.26 | |||||
Cash From Operations, 5 Yr. CAGR % | 36.28 | 37.87 | 32.48 | 30.72 | 57.45 | |||||
Capital Expenditures, 5 Yr. CAGR % | 44.98 | 28.95 | 31.87 | 17.47 | 20.07 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 26.57 | 19.67 | 6.65 | -1.72 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 26.67 | 20 | 7.01 | -1.64 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 21.67 | 17.61 | 17.84 | 19.14 |
Select your edition
All financial news and data tailored to specific country editions
















